TCM Formulas Show Symptom and Lab Gains in Cholelithiasis, but Evidence Remains Fragile
Thirteen randomized trials with 1,364 patients now sit at the center of a new synthesis on cholelithiasis and traditional Chinese medicine. The analysis examined liver-soothing, gallbladder-benefiting, and heat-clearing formulas, then layered on prescription mining, network pharmacology, and molecular docking to connect bedside effects with possible biologic mechanisms. The clinical signal was favorable for herbal formulas overall, yet the certainty of the evidence stayed low to very low, which keeps the findings in exploratory territory rather than practice-changing territory.
A clear theme ran through the ranking results: specific formulas repeatedly surfaced near the top of the network comparisons. Self-prepared Danshi Decoction ranked highest for total effective rate, the Shugan Lidan Qingre formula performed best for TCM syndrome scores, and Rongpai Danshi Capsules appeared strongest for lowering serum AST and ALT. Those are not trivial endpoints in gallstone disease, where symptom burden, biliary irritation, and hepatobiliary laboratory abnormalities can shape treatment choice long before surgery enters the discussion.
Clinical Rankings Favored Herbal Therapy Over Conventional Western Medicine
The network meta-analysis compared 12 formulas and conventional Western medicine across the eligible trials. Herbal formulas outperformed conventional Western medicine on the pooled clinical efficacy outcome, and the most favorable rankings came from formulas rooted in the liver-dispersing and bile-promoting tradition. SUCRA values placed self-prepared Danshi Decoction at 88.2% for total effective rate, Shugan Lidan Qingre formula at 85.7% for TCM syndrome score improvement, and Rongpai Danshi Capsules at 99.9% for AST and 100.0% for ALT reduction.
Those rankings deserve careful reading. SUCRA ordering reflects relative probability of being the best option within the dataset, not proof of superiority in a broad clinical sense. Small trial networks, heterogeneous comparators, and variable outcome definitions can inflate apparent precision. Even so, the repeated appearance of the same therapeutic class across multiple endpoints suggests the formulas may be affecting more than one pathway at once: biliary secretion, inflammatory tone, and perhaps hepatocellular stress.
Adverse events were described as mild and self-limiting.
Why Inflammation and Lipid Handling Matter in Gallstone Disease
The biological hypothesis is plausible enough to merit attention. Cholelithiasis is not only a mechanical problem of stone formation; it also involves biliary stasis, inflammatory signaling, and metabolic derangements that influence bile composition. Network pharmacology identified active compounds such as quercetin, wogonin, paeoniflorin, and aloe-emodin, with predicted effects on IL-6, IL-1β, and TNF-α. Those targets sit squarely inside inflammatory cascades that can amplify mucosal irritation and worsen hepatobiliary dysfunction.
The enrichment analysis also pointed toward lipid-metabolism pathways. In practical terms, that matters because altered cholesterol handling and bile acid balance are central to stone formation. A formula that dampens inflammatory mediators while nudging lipid processing in a more favorable direction offers a coherent mechanistic story, even if the story remains inferential until confirmed in experimental and clinical work.
Prescription Mining Pointed to a Small Core Herb Set
Apriori-based prescription mining distilled the formulas down to a recurring pattern. The remedies were predominantly cold in nature, combined bitter, pungent, and sweet flavors, and clustered around the spleen, liver, and stomach meridians. The therapeutic logic centered on clearing heat, draining dampness, soothing the liver, and promoting gallbladder function. Eight core herbs appeared to drive the pattern across the formulas.
This kind of data mining does more than catalog tradition. It identifies reproducible combinations that may explain why some formulas behave similarly across different studies, even when individual prescriptions vary. In a disease as heterogeneous as cholelithiasis, where pain, dyspepsia, biliary colic, and biochemical abnormalities do not always move together, a convergent herb pattern may be more clinically relevant than any single ingredient in isolation.
Docking Results Matched the Predicted Anti-Inflammatory Targets
Molecular docking added one more layer to the analysis. The top active compounds showed favorable binding affinities with the core targets, supporting the network pharmacology map rather than contradicting it. IL-6, IL-1β, and TNF-α again emerged as biologically meaningful nodes, reinforcing the idea that these formulas may operate through multi-target modulation rather than one dominant receptor interaction.
That multi-target structure fits the complexity of gallstone disease. A single agent aimed only at pain or only at bile composition may miss part of the pathophysiology. By contrast, a therapy that influences inflammation and metabolism together could explain why symptom scores and liver enzyme outcomes both improved in parts of the network. The mechanistic plausibility is stronger than for many traditional remedy claims, but plausibility is not the same as clinical proof.
Low Certainty Keeps the Results in Hypothesis-Generating Territory
CINeMA rated the certainty of evidence as low to very low. This is the central restraint on interpretation. The evidence network was limited, the study designs varied, and heterogeneity remained a concern. Those constraints make the ranking results and syndrome-differentiation strategies exploratory rather than definitive.
The investigators also relied on a mix of direct and indirect comparisons, which is useful for mapping a crowded treatment field but vulnerable to assumptions that are not always met in small trial ecosystems. When the comparator structure is thin, apparently strong rankings can shift if one or two studies are removed or if outcome definitions change. The sensitivity analyses helped, yet they cannot fully substitute for larger, rigorously blinded, multicenter trials.
For now, the most defensible reading is straightforward: liver-dispersing, bile-inducing, and heat-clearing TCM formulas showed potential benefit in conservative management of cholelithiasis, with the strongest signals appearing in total effective rate, TCM syndrome scores, and transaminase reduction. The gap between signal and certainty remains wide enough that the next step has to be better trials, not broader clinical adoption. Future work will need multicenter double-blind randomization, tighter comparator selection, and laboratory validation in vitro and in vivo if these formulas are going to move from promising network rankings to reliable bedside tools.